Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Neil Tanday, Peter R. Flatt, Nigel Irwin
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 526-541
Open Access | Times Cited: 24

Showing 24 citing articles:

The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 58
Interkingdom signaling between gastrointestinal hormones and the gut microbiome
Xinyu Zhao, Ye Qiu, Lanfan Liang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Islet effects of cholecystokinin and exploitation in diabetes
Neil Tanday, Nigel Irwin, Peter R. Flatt
Elsevier eBooks (2025), pp. 305-325
Closed Access
A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency
Xiaoyan Wang, Ying Yun, Lili Chen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 107, pp. 117761-117761
Closed Access | Times Cited: 3
Pancreatic islet cell plasticity: Pathogenic or therapeutically exploitable?
Neil Tanday, Andrei I. Tarasov, R. Charlotte Moffett, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 16-31
Open Access | Times Cited: 8
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
Mengqing Zhang, Chu Lin, Xiaoling Cai, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 806-815
Closed Access | Times Cited: 2
New developments in the prospects for GLP‐1 therapy
Stefan Trapp, S. Clare Stanford
British Journal of Pharmacology (2022) Vol. 179, Iss. 4, pp. 489-491
Open Access | Times Cited: 11
Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 12, pp. 2353-2363
Open Access | Times Cited: 11
GLP-1R mediates idebenone-reduced blood glucose in mice
Xin Zhao, Qingxuan Zeng, Siting Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117202-117202
Open Access | Times Cited: 1
Amplifying the antidiabetic actions of glucagon‐like peptide‐1: Potential benefits of new adjunct therapies
Neil Tanday, Peter R. Flatt, Nigel Irwin
Diabetic Medicine (2021) Vol. 38, Iss. 12
Open Access | Times Cited: 9
The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
Dr Ali Shami, John Sousou, Einas Batarseh, et al.
Cureus (2023)
Open Access | Times Cited: 3
A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control
Aimee Coulter‐Parkhill, SWM. Dobbin, Neil Tanday, et al.
Biochemical Pharmacology (2023) Vol. 212, pp. 115544-115544
Open Access | Times Cited: 3
The influence of parental high-fat high-sugar diet on the gut-brain axis in male offspring
Helena César, Marcela Nascimento Sertorio, Aline Boveto Santamarina, et al.
Food Research International (2022) Vol. 160, pp. 111706-111706
Closed Access | Times Cited: 5
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Natalie Klempel, Keith Thomas, J. Michael Conlon, et al.
Peptides (2022) Vol. 157, pp. 170877-170877
Open Access | Times Cited: 5
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats
Ananyaa Sridhar, Dawood Khan, Mahmoud Abdelaal, et al.
PLoS ONE (2022) Vol. 17, Iss. 9, pp. e0274788-e0274788
Open Access | Times Cited: 5
Sustained metabolic benefits of ΔTRTX‐Ac1, a tarantula venom‐derived peptide, when administered together with exenatide in high‐fat fed mice
Aimee Coulter‐Parkhill, Neil Tanday, Diego Cobice, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 329-338
Open Access | Times Cited: 2
The role of GDF15 in food intake and appetitive behaviour
Irène Cimino, Anthony P. Coll
Current Opinion in Endocrine and Metabolic Research (2021) Vol. 22, pp. 100299-100299
Closed Access | Times Cited: 5
In the land of not-unhappiness: On the state-of-the-art of targeting aging and age-related diseases by biomedical research
Eirini Klinaki, Mikołaj Ogrodnik
Mechanisms of Ageing and Development (2024) Vol. 219, pp. 111929-111929
Closed Access
Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan
Muhammad Daoud Butt, Siew Chin Ong, Azra Rafiq, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access
Benefits of GLP-1 Agonist

DHR Proceedings (2023)
Open Access | Times Cited: 1
Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese
Yanling Liang, Ling Chen, Tong Wang, et al.
Asian Journal of Surgery (2022) Vol. 46, Iss. 2, pp. 1000-1001
Open Access | Times Cited: 2
Specific interaction of insulin receptor and GLP-1 receptor mediates crosstalk between their signaling
Yubo Wang, Xiaohan Song, Yan Wang, et al.
Biochemical and Biophysical Research Communications (2022) Vol. 636, pp. 31-39
Closed Access | Times Cited: 2
Promising directions in the treatment of chronic heart failure: improving old or developing new ones?
V. V. Kalyuzhin, А. T. Teplyakov, И. Д. Беспалова, et al.
Bulletin of Siberian Medicine (2022) Vol. 21, Iss. 3, pp. 181-197
Open Access | Times Cited: 1
Page 1

Scroll to top